CAR-T Therapy Beyond B-Cell Hematological Malignancies.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI

Hematologic Neoplasms*/therapy ; Hematologic Neoplasms*/immunology ; Immunotherapy, Adoptive*/methods ; Receptors, Chimeric Antigen*/immunology; Humans ; B-Lymphocytes/immunology ; T-Lymphocytes/immunology ; Animals

Despite the advances of CAR-T cells in certain hematological malignancies, mostly from B-cell derivations such as non-Hodgkin lymphomas, acute lymphoblastic leukemia and multiple myeloma, a significant portion of other hematological and non-hematological pathologies can benefit from this innovative treatment, as the results of clinical studies are demonstrating. The clinical application of CAR-T in the setting of acute T-lymphoid leukemia, acute myeloid leukemia, solid tumors, autoimmune diseases and infections has encountered limitations that are different from those of hematological B-cell diseases. To overcome these restrictions, strategies based on different molecular engineering platforms have been devised and will be illustrated below. The aim of this manuscript is to provide an overview of the CAR-T application in pathologies other than those currently treated, highlighting both the limits and results obtained with these settings.

Lancet. 2020 Sep 19;396(10254):839-852. (PMID: 32888407)
Nat Med. 2024 Dec;30(12):3687-3696. (PMID: 39227445)
Cell. 2021 Dec 9;184(25):6017-6019. (PMID: 34890549)
Lung Cancer. 2012 May;76(2):138-43. (PMID: 22153832)
Elife. 2020 Mar 31;9:. (PMID: 32228854)
N Engl J Med. 2018 Feb 1;378(5):439-448. (PMID: 29385370)
Mol Ther Oncolytics. 2020 Aug 08;18:504-524. (PMID: 32953984)
Front Endocrinol (Lausanne). 2018 Aug 24;9:483. (PMID: 30197623)
Hum Gene Ther. 2002 Nov 1;13(16):1971-80. (PMID: 12427307)
Blood. 1991 Apr 1;77(7):1546-54. (PMID: 1826223)
Nature. 2019 Jul;571(7765):403-407. (PMID: 31217581)
J Virol. 2010 Apr;84(8):4083-8. (PMID: 20147393)
Cell. 2021 Feb 18;184(4):861-880. (PMID: 33497610)
Nat Rev Cancer. 2020 Jun;20(6):300. (PMID: 32265522)
Nat Rev Drug Discov. 2020 Mar;19(3):185-199. (PMID: 31900462)
Int J Mol Sci. 2021 Jun 29;22(13):. (PMID: 34209703)
Blood. 2007 Oct 1;110(7):2659-66. (PMID: 17609428)
Pediatr Blood Cancer. 2016 Oct;63(10):1780-5. (PMID: 27304202)
J Infect Dis. 2020 Aug 4;222(5):853-862. (PMID: 32285133)
Immunol Rev. 2014 Jan;257(1):91-106. (PMID: 24329792)
Front Oncol. 2023 Feb 02;13:1103149. (PMID: 36816959)
Cancers (Basel). 2022 Jul 08;14(14):. (PMID: 35884391)
Int J Mol Sci. 2023 Feb 20;24(4):. (PMID: 36835603)
Gastroenterology. 2008 Jan;134(1):239-47. (PMID: 18166356)
Trends Cancer. 2018 Nov;4(11):741-754. (PMID: 30352677)
Nat Rev Dis Primers. 2015 Oct 01;1:15035. (PMID: 27188527)
Hum Gene Ther. 2018 May;29(5):626-639. (PMID: 29409351)
Cancer Cell. 2021 Jul 12;39(7):885-888. (PMID: 34256903)
Crit Rev Biotechnol. 2022 Nov;42(7):1079-1098. (PMID: 34957875)
Cancer Res. 2013 Jun 1;73(11):3371-80. (PMID: 23633494)
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37. (PMID: 11252954)
Cancers (Basel). 2021 Jun 01;13(11):. (PMID: 34206026)
Nat Rev Clin Oncol. 2020 Jan;17(1):33-48. (PMID: 31548601)
Nat Rev Drug Discov. 2020 Mar;19(3):200-218. (PMID: 31907401)
Front Oncol. 2020 Feb 28;10:262. (PMID: 32185132)
Cancers (Basel). 2023 Feb 21;15(5):. (PMID: 36900151)
Mol Cancer. 2023 Jan 30;22(1):20. (PMID: 36717905)
Front Immunol. 2022 Aug 03;13:953849. (PMID: 35990652)
Cancer Immunol Res. 2016 Oct;4(10):869-880. (PMID: 27549124)
Cancers (Basel). 2021 Sep 24;13(19):. (PMID: 34638268)
Lancet. 2021 Aug 7;398(10299):491-502. (PMID: 34097852)
N Engl J Med. 2024 Feb 22;390(8):687-700. (PMID: 38381673)
Mol Ther Oncolytics. 2023 Sep 16;31:100728. (PMID: 37822488)
Glycoconj J. 2015 Nov;32(8):575-613. (PMID: 26239922)
Cell Rep. 2017 Dec 12;21(11):3205-3219. (PMID: 29241547)
Pharmacol Ther. 2021 Mar;219:107709. (PMID: 33091428)
Front Oncol. 2012 Apr 18;2:34. (PMID: 22655270)
Nat Rev Clin Oncol. 2021 Nov;18(11):677-678. (PMID: 34580474)
Front Immunol. 2022 Feb 03;13:841107. (PMID: 35185932)
Nat Commun. 2021 Oct 28;12(1):6228. (PMID: 34711823)
Mol Ther. 2019 Jul 3;27(7):1262-1274. (PMID: 31043341)
Oncoimmunology. 2021 Mar 18;10(1):1899469. (PMID: 33796409)
Sci Transl Med. 2021 Nov 17;13(620):eabh0272. (PMID: 34788079)
Biomedicines. 2022 Sep 30;10(10):. (PMID: 36289703)
PLoS One. 2015 May 07;10(5):e0125994. (PMID: 25951175)
J Immunother Cancer. 2021 Sep;9(9):. (PMID: 34531250)
Blood. 2019 Dec 12;134(24):2149-2158. (PMID: 31697826)
iScience. 2021 Nov 19;24(11):103295. (PMID: 34693218)
Mol Ther. 2019 May 8;27(5):947-959. (PMID: 30852138)
J Hematol Oncol. 2021 Oct 9;14(1):162. (PMID: 34627328)
Mol Ther Oncolytics. 2022 Nov 03;27:224-238. (PMID: 36420307)
Nat Rev Microbiol. 2021 Dec;19(12):759-773. (PMID: 34168328)
Mol Med Rep. 2021 Mar;23(3):. (PMID: 33495835)
Blood. 2017 Apr 27;129(17):2395-2407. (PMID: 28246194)
JCI Insight. 2020 Feb 27;5(4):. (PMID: 31999649)
Talanta. 2022 Mar 1;239:123146. (PMID: 34942484)
Leukemia. 2021 Nov;35(11):3282-3286. (PMID: 33833386)
J Biol Chem. 2010 Aug 27;285(35):27213-27223. (PMID: 20581115)
J Immunother. 2010 Oct;33(8):780-8. (PMID: 20842059)
Nat Med. 2020 Nov;26(11):1776-1787. (PMID: 32868878)
Mol Ther. 2015 Jan;23(1):184-91. (PMID: 25174587)
Biomed Mater. 2021 Mar 03;16(3):. (PMID: 33540396)
Am J Surg Pathol. 2003 Nov;27(11):1418-28. (PMID: 14576474)
J Immunother Cancer. 2020 Oct;8(2):. (PMID: 33127653)
Oncol Lett. 2019 Dec;18(6):5681-5690. (PMID: 31788040)
Transl Oncol. 2020 Nov;13(11):100838. (PMID: 32745961)
Nat Rev Cancer. 2016 Dec;16(12):789-802. (PMID: 27687982)
Gut. 2016 Mar;65(3):512-23. (PMID: 25661083)
Cancer Cell Int. 2024 Apr 15;24(1):133. (PMID: 38622705)
J Hematol Oncol. 2018 May 2;11(1):60. (PMID: 29716633)
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7788-E7797. (PMID: 27849617)
N Engl J Med. 2019 May 2;380(18):1726-1737. (PMID: 31042825)
Ann Oncol. 2022 Mar;33(3):259-275. (PMID: 34923107)
Front Oncol. 2021 Aug 06;11:720501. (PMID: 34422667)
Cancers (Basel). 2020 Jul 20;12(7):. (PMID: 32698361)
Int J Mol Sci. 2021 Jun 18;22(12):. (PMID: 34207342)
Lancet Oncol. 2024 Mar;25(3):376-387. (PMID: 38309282)
Nat Rev Cancer. 2010 Feb;10(2):116-29. (PMID: 20094046)
Blood. 2022 Oct 6;140(14):1583-1591. (PMID: 35580162)
Leukemia. 2018 May;32(5):1157-1167. (PMID: 29479065)
J Immunother Cancer. 2022 Dec;10(12):. (PMID: 36564128)
Oncoimmunology. 2016 Oct 28;5(12):e1251539. (PMID: 28123893)
N Engl J Med. 2017 Dec 28;377(26):2531-2544. (PMID: 29226797)
Mol Ther. 2020 Oct 7;28(10):2237-2251. (PMID: 32592688)
Biomolecules. 2019 Jul 27;9(8):. (PMID: 31357634)
Cancers (Basel). 2022 Feb 24;14(5):. (PMID: 35267471)
Oncoimmunology. 2013 Nov 1;2(11):e26618. (PMID: 24404430)
Int J Mol Sci. 2021 Jun 07;22(11):. (PMID: 34200284)
Mol Ther. 2017 Sep 6;25(9):2202-2213. (PMID: 28676343)
Stem Cell Rev Rep. 2019 Jun;15(3):443-447. (PMID: 30826931)
Sci Transl Med. 2022 Jan 19;14(628):eabg3072. (PMID: 35044789)

Keywords: CAR-T in hematology; CAR-T in solid neoplasia; infectious and autoimmune disease; tumor immunosuppression; tumor microenvironment

0 (Receptors, Chimeric Antigen)

Date Created: 20250110 Date Completed: 20250110 Latest Revision: 20250113

20250113

PMC11719893

10.3390/cells14010041

39791742